Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers
Authors:
- Miguel Gómez-BallesterosMGMiguel Gómez-Ballesteros
- Vanessa Andrés-GuerreroVAVanessa Andrés-Guerrero
- Francisco Jesús ParraFPFrancisco Jesús Parra
- Jorge MarinichJMJorge Marinich
- Beatriz De-Las-HerasBDBeatriz De-Las-Heras
- Irene Teresa Molina-MartínezIMIrene Teresa Molina-Martínez
- Blanca Vázquez-LasaBVBlanca Vázquez-Lasa
- Julio San RománJRJulio San Román
- Rocío Herrero-VanrellRHRocío Herrero-Vanrell
Open Access
Abstract
Topical application of drops containing ocular drugs is the preferred non-invasive route to treat diseases that affect the anterior segment of the eye. However, the formulation of eye drops is a major challenge for pharmacists since the access of drugs to ocular tissues is restricted by several barriers. Acetazolamide (ACZ) is a carbonic anhydrase inhibitor used orally for the treatment of ocular hypertension in glaucoma. However, large ACZ doses are needed which results in systemic side effects. Recently, we synthesized copolymers based on 2-hydroxyethyl methacrylate (HEMA) and a functionalized three-arm poloxamer star (Bayfit-MA). The new material (HEMA/Bayfit-MA) was engineered to be transformed into nanoparticles without the use of surfactants, which represents a significant step forward in developing new ophthalmic drug delivery platforms. Acetazolamide-loaded nanocarriers (ACZ-NPs) were prepared via dialysis (224 ± 19 nm, −17.2 ± 0.4 mV). The in vitro release rate of ACZ was constant over 24 h (cumulative delivery of ACZ: 83.3 ± 8.4%). Following standard specifications, ACZ-NPs were not cytotoxic in vitro in cornea, conjunctiva, and macrophages. In normotensive rabbits, ACZ-NPs generated a significant intraocular pressure reduction compared to a conventional solution of ACZ (16.4% versus 9.6%) with the same dose of the hypotensive drug (20 µg). In comparison to previously reported studies, this formulation reduced intraocular pressure with a lower dose of ACZ. In summary, HEMA:Bayfit-MA nanoparticles may be a promising system for ocular topical treatments, showing an enhanced ocular bioavailability of ACZ after a single instillation on the ocular surface.Keywords
Funding Information
- University of California Merced (UCM-920415)
- FEDER-CICYT (FIS-PI17/00079, PI17/00466)
- MINECO/AEI/FEDER, UE (MAT2017-83858-C2)
- ISCII-FEDER RETICS (OFTARED RD16/0008)
This publication has 47 references indexed in Scilit:
- Comparison of the In Vitro Tolerance and In Vivo Efficacy of Traditional Timolol Maleate Eye Drops versus New Formulations with Bioadhesive PolymersInvestigative Ophthalmology & Visual Science, 2011
- Applications of nanoparticles in ophthalmologyProgress in Retinal and Eye Research, 2010
- Preservatives in eyedrops: The good, the bad and the uglyProgress in Retinal and Eye Research, 2010
- Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cellsClinical & Experimental Ophthalmology, 2008
- Challenges and obstacles of ocular pharmacokinetics and drug deliveryAdvanced Drug Delivery Reviews, 2006
- Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticlesNanomedicine: Nanotechnology, Biology and Medicine, 2006
- Micellization and Gelation of Aqueous Solutions of Star-Shaped PLLA−PEO Block CopolymersMacromolecules, 2003
- PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drugJournal of Controlled Release, 1999
- Mixed micelles in drug deliveryNature, 1992
- Nanocapsule formation by interfacial polymer deposition following solvent displacementInternational Journal of Pharmaceutics, 1989